Fresenius Kabi Oncology Limited
Add to watch list to get report alerts
BSE Code:
532545
NSE Code:
FKONCO
Business Profile
Business Profile
Dabur Pharma (DABURPH) is a specialty pharmaceuticals company with a focus on oncology. Earlier a part of Dabur Industries, the company completed the demerger process in December 2003.
The fully integrated pharmaceutical business of Dabur Pharma covers the oral and injectable finished dosage forms and active pharmaceutical ingredients and intermediates. Products include anti-cancer drugs like Anastrozole, Oxaliplatin, Zoledronic Acid, etc; drug intermediates like Baccatin III, Epoxy Propoxy Carbazole, etc; calcium regulators like Alendronate Sodium BP. The company has its manufacturing units for finished dosage forms in Bordon (UK) and Baddi (India), while the active pharmaceutical ingredients (APIs) are manufactured in Kalyani (India) and some products come from Dabur India`s Sahibabad facilities.
The company launched Paclitaxel Nanoparticles, an indigenously developed novel drug delivery system (NDDS), and received final approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Epirubicin injection 50 mg and 200 mg. The company acquired the entire oncology sales and distribution business from its partner Biosciences Co. in Thailand, while its subsidiary Dabrur Oncology set up Dabur Pharma US, to handle sales and marketing in US. The company has a 10-year exclusive agreement with Abbott Labs for generics in the US market.
The company has overseas offices in UK, Malaysia, Russia, Thailand and Philippines. Products are available in more than 40 countries across the globe through a marketing network including Asia Pacific, Commonwealth of Independent States, India, Latin America, North America and the European Union. It recently forayed into Pakistan and Turkmenistan.
The registered office is at 3, Factory Road, Adj. Safdarjung Hospital, New Delhi-110029.
Financials
Dabur Pharma registered a 1912.17% growth in net profits to Rs 1334.07 million for the quarter ended June 2007 from a profit of Rs 66.30 million for the quarter ended June 2006Net Sales declined 8.86% to Rs 714.33 million for the quarter ended June 2007 from Rs 783.74 million for the quarter ended June 2006.Total income dipped 3.87% to Rs 761.48 million, from Rs 792.14 million for the quarter ended June 2006.The earnings per share (EPS) of the company stood at Rs 8.52 in the quarter ended June 2007 .
Recent Developments
24-OCT-07
Dabur Pharma announced that it signed a supply & distribution agreement on Oct. 24, 2007 with Combino Pharm, one of Spain`s leading generic companies, to distribute and market generic oncology products in the Spanish market.
24-AUG-07
Dabur Pharma has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Epirubicin injection 50mg and 200mg.